The 36-Marker Problem: Why Next-Day CAR-T Manufacturing Will Break Without AI-Driven Spectral Flow Cytometry

The Collision Course Two forces are on a collision course in cell therapy manufacturing, and nobody is talking about it. Force 1: Spectral panels are getting bigger. In May 2025, a team at USC published a 36-marker spectral flow cytometry panel in Molecular Therapy that simultaneously profiles phenotype, metabolism, function, activation, and exhaustion of CAR-T cells during manufacturing. They found that Day 5 products retain stem-like, metabolically active CD4+ Th1 cells with high proliferative capacity, while Day 10 products become terminally differentiated CD8+ Tc1 populations. The implication is staggering: when you harvest your CAR-T cells matters more than how you engineer them [1]. Force 2: Manufacturing is getting faster. Next-day CAR-T manufacturing — functional T cells in 24 hours without activation or expansion — is now technically possible . These cells show higher per-cell anti-leukemic activity than standard 7-14 day products. But there's a catch: CAR expression requires